SCHEMBL6755724

SCHEMBL6755724

Nc1cc(Cl)cc(NC(=O)C=Cc2ccccn2)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ EGFR P00533 3/20 0.54
▸ MAPT P10636 2/20 0.48
▸ KDM4E B2RXH2 1/20 0.48
▸ MMP1 P03956 3/20 0.46
▸ MMP2 P08253 3/20 0.46
▸ MMP9 P14780 3/20 0.46
▸ MAOA P21397 3/20 0.46
▸ MAOB P27338 3/20 0.46
▸ SIRT2 Q8IXJ6 1/20 0.45
▸ SIRT1 Q96EB6 1/20 0.45
▸ SIRT3 Q9NTG7 1/20 0.45
▸ NPC1 O15118 5/20 0.44
▸ RAB9A P51151 5/20 0.44
▸ LMNA P02545 3/20 0.44
▸ SMN1; SMN2 Q16637 2/20 0.44
▸ TP53BP1 Q12888 1/20 0.44
▸ MEN1 O00255 4/20 0.43
▸ KMT2A Q03164 4/20 0.43
▸ CYP1A2 P05177 2/20 0.43
▸ CYP3A4 P08684 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6755721 1.00 EGFR (0.54) EGFRMAPTKDM4EMMP1MMP2
SCHEMBL6756739 0.80 RAB9A (0.66) EGFRMAPTKDM4EMMP2MAOA
SCHEMBL6756745 0.80 RAB9A (0.66) EGFRMAPTKDM4EMMP2MAOA
SCHEMBL6756742 0.80 RAB9A (0.66) EGFRMAPTKDM4EMMP2MAOA
SCHEMBL6755622 0.75 MAOB (0.65) EGFRMAPTKDM4EMMP1MMP2
SCHEMBL6755620 0.75 MAOB (0.65) EGFRMAPTKDM4EMMP1MMP2
SCHEMBL6756578 0.75 EGFR (0.51) EGFRMAPTKDM4EMMP1MMP2
SCHEMBL6755624 0.75 MAOB (0.65) EGFRMAPTKDM4EMMP1MMP2
SCHEMBL6756577 0.75 EGFR (0.51) EGFRMAPTKDM4EMMP1MMP2
SCHEMBL6756576 0.75 EGFR (0.51) EGFRMAPTKDM4EMMP1MMP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040087798-A1 Novel amide compounds FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-05-06 — — US disclosed
EP-1264820-A1 NOVEL AMIDE COMPOUNDS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2002-12-11 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040087798-A1 Novel amide compounds H1-2, H1-0, H1-3 EGFR 1431/4885MAPT 3247/4885KDM4E 1506/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback